[ad_1] Alex Huth (left), Shailee Jain (center) and Jerry Tang (right) prepare to collect brain activity data in the Biomedical Imaging Center at The University of Texas at Austin. The researchers trained their semantic decoder on dozens of hours of brain activity data from participants, collected in an fMRI scanner. Photo: Nolan Zunk/University of Texas…
[ad_1] Democratic and Republican attorneys general in nearly half of U.S. states are calling on Medicare to provide unrestricted coverage of antibody treatments for Alzheimer’s disease, according to a letter released Monday. The push by attorneys general from 23 states, Washington D.C., and two U.S. territories adds to mounting pressure on the federal Centers for…
[ad_1] Juanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the coming years, putting them at risk of developing more severe disease as they wait months or perhaps years for a diagnosis. The U.S. health-care system…
[ad_1] While there has been plenty of buzz about how successful patients have been in losing weight while taking a new class of obesity medications, there is a growing realization that when people stop taking these pricey drugs, the pounds can creep back on. There was a frank discussion of this on Eli Lilly’s first-quarter…
[ad_1] Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016. David A. Grogan | CNBC Carl Icahn on Friday called Illumina’s first-quarter results “very disappointing” and slammed the DNA sequencing company’s new plans to cut costs. The activist investor, who owns a 1.4% stake in Illumina, is in a heated proxy…
[ad_1] Jenny Craig has alerted employees to potential mass layoffs as it begins “winding down physical operations” and hunts for a buyer, according to communications the weight-loss company sent some staffers this week. The company said it “has been going through a sales process for the last couple of months,” according to a document titled…
[ad_1] Eli Lilly‘s first-quarter earnings missed expectations Thursday, but the pharmaceutical company raised its full-year guidance. Before the earnings release, the company also reported positive data on its weight loss drug tirzepatide. related investing news Eli Lilly’s stock closed nearly 4% higher at $390.35 a share. The company’s revenue fell 11% compared with the same…
[ad_1] Patients who took Eli Lilly‘s weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory…
[ad_1] Activists for transgender rights gather in front of the US Supreme Court in Washington, DC, on April 1, 2023. Andrew Caballero-reynolds | AFP | Getty Images The Department of Justice is suing Tennessee for allegedly discriminating against transgender youth with a new state law banning the use of puberty blockers, hormones, and other medical…
[ad_1] In this photo illustration, packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland. Anna Moneymaker | Getty Images The abortion pill mifepristone is either banned or restricted to varying degrees in 27 states despite a Supreme Court decision that — for now — maintains Food…
